Difference between revisions of "Ziv-aflibercept (Zaltrap)"
Jump to navigation
Jump to search
m (PeterYang moved page Aflibercept (Zaltrap) to Ziv-aflibercept (Zaltrap): FDA approval, new name) |
(FDA approval & extra information) |
||
| Line 1: | Line 1: | ||
| − | Also known as VEGF trap. When used for | + | '''FDA approved 8/3/2012'''. Also known as aflibercept or VEGF trap. When used for macular degeneration, it is known as Eylea. |
==General information== | ==General information== | ||
| − | Class/mechanism: fusion protein | + | Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PLGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.<ref name="insert">[http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf Ziv-aflibercept (Zaltrap) package insert]</ref><ref>[[Media:Zivaflibercept.pdf|Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)]]</ref><ref>[http://www.regeneron.com/zaltrap/ Zaltrap manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Clinical trials== | ||
| + | *[http://new.ecco-org.eu/ecco_content/2011StockholmLateBreakingflipbook/files/assets/seo/page9.html VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)]<ref>J. Tabernero, E. Van Cutsem, R. Lakomy, J. Prausova, P. Ruff, G. Van Hazel, V. Moiseyenko, D. Ferry, J. McKendrick, K. Soussan-Lazard, E. Boelle, C. Allegra. [http://new.ecco-org.eu/ecco_content/2011StockholmLateBreakingflipbook/files/assets/seo/page9.html VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)]. [http://stockholm2011.ecco-org.eu/Programme.aspx 2011 European Multidisciplinary Congress]. Abstract 6LBA. Presented September 25, 2011.</ref> | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *Brief patient counseling information is available on [http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf#page=17 pages 16-17 of the package insert].<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)] -- note: this is for Eylea, not Zaltrap<ref>[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)] -- note: this is for Eylea, not Zaltrap<ref>[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 23:09, 3 August 2012
FDA approved 8/3/2012. Also known as aflibercept or VEGF trap. When used for macular degeneration, it is known as Eylea.
General information
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PLGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Clinical trials
- VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)[4]
Patient drug information
- Brief patient counseling information is available on pages 16-17 of the package insert.[1]
- Aflibercept patient drug information (UpToDate) -- note: this is for Eylea, not Zaltrap[5]
References
- ↑ 1.0 1.1 1.2 Ziv-aflibercept (Zaltrap) package insert
- ↑ Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)
- ↑ Zaltrap manufacturer's website
- ↑ J. Tabernero, E. Van Cutsem, R. Lakomy, J. Prausova, P. Ruff, G. Van Hazel, V. Moiseyenko, D. Ferry, J. McKendrick, K. Soussan-Lazard, E. Boelle, C. Allegra. VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC). 2011 European Multidisciplinary Congress. Abstract 6LBA. Presented September 25, 2011.
- ↑ Aflibercept patient drug information (UpToDate)